Key result
Adding ezetimibe to high-dose statins proves cost-effective at ~$20,242 per QALY versus PCSK9 inhibitors.
Why the study?
International guidelines recommend add-on ezetimibe and PCSK9 inhibitors for secondary prevention of CVDs, but whether these regimens fit the Chinese healthcare system economically remains unclear.
Is adding ezetimibe and/or PCSK9 inhibitors to high-dose statins cost-effective for secondary prevention of cardiovascular disease in Chinese adults?
Is adding ezetimibe and/or PCSK9 inhibitors to high-dose statins cost-effective for secondary prevention of cardiovascular disease in Chinese adults?
In Chinese adults on high-dose statins for secondary CVD prevention, adding ezetimibe is cost-effective, whereas adding PCSK9 inhibitors requires a substantial price reduction to meet cost-effectiveness thresholds.
Answers are grounded in this paper and cite their sources.
Supports ezetimibe addition for secondary prevention in China; leaves open whether PCSK9i price cuts achieve cost-effectiveness thresholds.
OBJECTIVES: The latest international guideline recommended the add-on therapy of ezetimibe and PCSK9 inhibitors in selected people for the secondary prevention of cardiovascular diseases (CVDs). However, it remains unclear whether these regimens fit the Chinese healthcare system economically. METHODS: Based on the Chinese context, this simulation study evaluated four therapeutic strategies including the high-dose statin-only group, ezetimibe plus statin group, PCSK9 inhibitors plus statin group, and PCSK9 inhibitors plus ezetimibe plus statin group. The team developed a Markov model to estimate the incremental cost-effectiveness ratio (ICER). With each 1-yr cycle, the simulation subjects could have nonfatal cardiovascular events (stroke and/or myocardial infarction) or death (vascular or nonvascular death event) with a follow-up duration of 20 yr. Cardiovascular risk reduction was gathered from a network meta-analysis, and cost and utility data were gathered from hospital databases and published research. RESULTS: For Chinese adults receiving high-dose statins for secondary prevention of CVDs, the ICER was US$68,910 per quality-adjusted life year (QALY) for adding PCSK9 inhibitors, US$20,242 per QALY for adding ezetimibe, US$51,552 per QALY for adding both drugs. Given a threshold of US$37,655 (three times of Chinese GDP), the probability of cost-effectiveness is 2.9 percent for adding PCSK9 inhibitors, 53.1 percent for adding ezetimibe, and 16.8 percent for adding both drugs. To meet the cost-effectiveness, an acquisition price reduction of PCSK9 inhibitors of 33.6 percent is necessary. CONCLUSION: In Chinese adults receiving high-dose statins for the secondary prevention of CVDs, adding ezetimibe is cost-effective compared to adding PCSK9 inhibitors and adding both drugs.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2023) studied Cardiovascular disease. Ezetimibe and/or PCSK9 inhibitors vs. High-dose statin-only was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) (ICER US$20,242 per QALY for adding ezetimibe). In Chinese adults on high-dose statins for secondary CVD prevention, adding ezetimibe was cost-effective (ICER US$20,242/QALY) compared to adding PCSK9 inhibitors or both drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: